VYNE Therapeutics (VYNE) Interest Coverage Ratio (2017 - 2025)
VYNE Therapeutics (VYNE) posted Interest Coverage Ratio of 3771.0 for Q2 2025, down 3620.8% on a QoQ basis from 101.35 in Q4 2024, and down 2003.87% year-over-year from 198.07 in Q2 2024.
VYNE Therapeutics (VYNE) Interest Coverage Ratio (2017 - 2025) Analysis & Trends
VYNE Therapeutics' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 3771.0 for Q2 2025.
- Quarterly Interest Coverage Ratio fell 2003.87% year-over-year to 3771.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 21300.0 (down 3905.58% YoY) and the FY2025 annual result came in at 265.62, down 61195.55% from the prior year.
- Interest Coverage Ratio was 3771.0 for Q2 2025 at VYNE Therapeutics, down from 101.35 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 139.43 in Q4 2023 and bottomed at 6545.5 in Q3 2024.
- A 4-year average of 819.71 and a median of 20.78 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2021 — Interest Coverage Ratio soared 94.31% — and 2024, when it tumbled 31399.04%.
- VYNE Therapeutics' Interest Coverage Ratio stood at 2.74 in 2021, then jumped by 4983.17% to 139.43 in 2023, then slumped by 172.69% to 101.35 in 2024, then tumbled by 3620.8% to 3771.0 in 2025.
- Business Quant data shows VYNE's Interest Coverage Ratio at 3771.0 in Q2 2025, 101.35 in Q4 2024, and 6545.5 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -0.38 |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -3,771.00 |
| Dec 31, 2024 | -101.35 |
| Sep 30, 2024 | -6,545.50 |
| Jun 30, 2024 | -179.24 |
| Mar 31, 2024 | -105.43 |
| Dec 31, 2023 | 139.43 |
| Sep 30, 2023 | -20.78 |
| Jun 30, 2023 | -34.39 |
| Mar 31, 2023 | -19.58 |
| Dec 31, 2021 | 2.74 |
| Sep 30, 2021 | -3.10 |
| Jun 30, 2021 | -8.88 |
| Mar 31, 2021 | -9.19 |
| Dec 31, 2020 | 11.70 |
| Sep 30, 2020 | -21.51 |
| Jun 30, 2020 | -156.24 |
| Mar 31, 2020 | -37.38 |
| Dec 31, 2019 | -68.06 |
| Sep 30, 2019 | -8.24 |
| Jun 30, 2019 | -3.38 |